This is among the first and largest summaries of the use of neoadjuvant PD-1 inhibitor (nivolumab) in patients with resectable lung cancer. The safety profile was adequate, 20 of 21 patients underwent complete resection, and the pathologic major response rate was 45%. The response was similar regardless of PD-L1 status, and response was related to tumor mutational burden.
You are here:
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Submitted by: Mark Ferguson
Source: The New England Journal of Medicine
Keywords:
Author(s): Patrick M. Forde, Jamie E. Chaft, Kellie N. Smith, Valsamo Anagnostou, Tricia R. Cottrell,Matthew D. Hellmann, Marianna Zahurak, Stephen C. Yang, David R. Jones, Stephen Broderick, Richard J. Battafarano, Moises J. Velez, Natasha Rekhtman, Zachary Olah, Jarushka Naidoo, Kristen A. Marrone, Franco Verde, Haidan Guo, Jiajia Zhang, Justina X. Caushi, Hok Yee Chan, John-William Sidhom, Robert B. Scharpf, James White, Edward Gabrielson, Hao Wang,Gary L. Rosner, Valerie Rusch, Jedd D. Wolchok, Taha Merghoub, Janis M. Taube, Victor E. Velculescu, Suzanne L. Topalian, Julie R. Brahmer, Drew M. Pardoll
